DDIT3 and diffuse large B-cell lymphoma: Our outcomes are better than those previously reported for this subtype of DLBCL. This difference is difficult to reconcile but may reflect improvement in supportive care. Given our findings, we believe that a prospective trial of R-CHOP versus DA-REPOCH in patients with the ABC subtype of DLBCL is warranted.